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ABSTRACT
Introduction: Involvement of pre-existing
benign lesions by ductal carcinoma in situ
(DCIS) or lobular neoplasia (LN) can present
difficult diagnostic challenges, and can easily
cause misdiagnosis of invasive carcinoma and
over-management of localized disease. Our
objective was to gather the largest case series of
DCIS and LN involving sclerosing adenosis (SA),
and to report the characteristic features of these
lesions, in order to provide histologic criteria for
the diagnostician.
Methods: Our database was searched for core
biopsy material diagnosed as carcinoma in situ
involving adenosis. Glass slides and pathology
reports were reviewed. The cases were studied
for salient features, and clinical follow-up was
also obtained.
Results: Thirty-one cases of DCIS or LN
involving SA were obtained (12 cases of DCIS,
19 cases of LN including LCIS and ALH). His-
tomorphologic features commonly seen with
DCIS or LN involving SA included lobulocentric
architecture (31/31, 100%), myoepithelial cells
visible by H&E at least focally (31/31, 100%),
and separate areas of SA not involved by neo-
plasia (29/31, 93.5%). Features that were some-
times seen included hyaline basement
membranes surrounding the lesion (14/31,
45.2%), DCIS/LN apart from the area of
involvement by SA (16/31, 51.6%), and calcifi-
cations associated with DCIS/LN/SA (12/31,
38.7%). Features that were not commonly seen
included desmoplasia (6/31, 19.4%), dense
inflammation (4/31, 12.9%), and single epithe-
lial cells enveloped by flattened myoepithelial
cells (6/31, 19.4%). Of the ten cases of DCIS
with known follow-up, four showed DCIS
involving either SA or a complex SA on excision
(4/10, 40%), four had only DCIS (4/10, 40%),
one had DCIS with a small 1.8-mm focus of
predominantly tubular carcinoma (1/10, 10%),
and one showed invasive ductal carcinoma on
excision (1/10, 10%). The latter case of invasive
ductal carcinoma occurred in a patient who had
a delay of 3 years from diagnosis to surgical
resection. Of the eight cases of LN with surgical
follow-up, seven had LCIS (7/8, 87.5%), and one
showed only fibroadenoma and SA with no
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residual LN in the excised specimen (1/8,
12.5%). Importantly, no invasive carcinoma
was identified in any of the resections for LN
involving SA.
Conclusions: In our series of carcinoma in situ
(CIS) involving sclerosing adenosis diagnosed
on core biopsy, lobular lesions involving SA
were more common than ductal lesions. Ductal
and lobular carcinoma in situ involving
adenosis were best diagnosed by the low-power
appearance of a lobulocentric pattern of
growth. The most helpful diagnostic feature was
the observation of additional foci of carcinoma
in situ away from the adenosis. Immunohisto-
chemical stains for myoepithelial cells were
useful in particularly difficult cases. The pres-
ence of stromal desmoplasia does not preclude
the diagnosis of carcinoma in situ involving
adenosis. Knowledge of these diagnostic pearls
can reduce over-interpretation of CIS on core
biopsy and subsequent overtreatment.
Keywords: Adenosis; Breast; Core biopsy;
Ductal carcinoma in situ; Lobular carcinoma
in situ
Key Summary Points
Carcinoma in situ involving adenosis
(both ductal carcinoma in situ and lobular
carcinoma in situ) is a difficult diagnosis
to make on core needle biopsy and
therefore must be forefront in the mind of
the diagnostician.
Awareness of the lesion and the
characteristic morphology presented
herein can aide in rendering the
appropriate diagnosis and providing
recommendations for management of this
localized lesions.
When present, the recognition of
additional foci of carcinoma away from
the adenosis is a helpful feature.
Importantly, the presence of stromal
desmoplasia does not preclude the
diagnosis of carcinoma in situ involving
adenosis.
INTRODUCTION
The diagnosis of ductal carcinoma in situ (DCIS)
or lobular neoplasia (LN) involving a sclerosing
lesion can present difficult diagnostic chal-
lenges on limited biopsy material, and this
in situ disease can frequently be confused with
invasive carcinoma on core biopsy. Knowledge
of this diagnostic mimicker and its distinct
histopathology can aid decision-making and
prevent overdiagnosis and patient harm.
Sclerosing adenosis (SA) alone can present dif-
ficult diagnostic challenges, especially on lim-
ited core biopsy material. The involvement of
SA by ductal or LN can be particularly trouble-
some, since in florid cases it may mimic an
invasive carcinoma. However, if the possibility
of in situ neoplasia involving SA is considered,
the diagnosis can be straightforward. Certainly
immunohistochemistry can aid in the differen-
tial diagnosis, but if adenosis is not initially
considered by the practicing pathologist, the
opportunity to even employ immunohisto-
chemistry to arrive at the correct diagnosis will
be lost.
The purpose of this study was to provide
awareness of the differential diagnosis of CIS
involving adenosis and decrease the incidence
of over-interpretation of this lesion on core
biopsy and subsequent overtreatment. Herein
we provide histological criteria to define fea-
tures of ductal and lobular neoplasia involving
sclerosing adenosis on core biopsy, and exam-
ine the clinicopathological features of this dis-
ease occurring in patients. To the best of our
knowledge, this series represents the largest to
date of such lesions identified on core biopsy
with follow-up and serves to highlight this dif-
ficult diagnosis and diagnostic pearls necessary
to avoid overtreatment.
METHODS
Our computer files were searched for patients
who had undergone core needle biopsies of
mammographic abnormalities, specifically cases
of breast core needle biopsy specimens with a
dominant diagnosis of sclerosing adenosis
involved by either DCIS or LCIS/atypical lobular
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hyperplasia (ALH) from 1999 to present. Cases
with concomitant invasive carcinoma were
excluded. We obtained 31 cases: 12 cases of
DCIS and 19 cases of LN (for the purpose of this
paper, no distinction was made between LCIS
and ALH). The slides were reviewed by two
pathologists, both with expertise in breast neo-
plasia (DR, LM). Information about clinical
presentation and follow-up and/or resection
was also obtained. This was a lab-based and
quality improvement project, and as such did
not meet institutional review board criteria for
review.
RESULTS
The average patient age was 54.1 years, with an
age range of 21–65 years. Presenting clinical
findings included masses (6/31, 19.4%), calcifi-
cations on mammography (21/31, 67.7%),
architectural asymmetry or distortion on
mammography (3/31, 9.7%), and an area of
enhancement on MRI (1/31, 3.2%).
The lesions were sampled by ultrasound-
guided core biopsy (6/31, 19.4%), stereotactic-
guided core biopsy (21/31, 67.7%), MRI-guided
core biopsy (2/31, 6.5%), or by biopsy not
specified (2/31, 6.5%). For stereotactic-guided
core biopsy, the cores ranged from 9- to
11-gauge, and the number of cores varied from
5 to 18. For ultrasound-guided core biopsy, the
cores ranged from 16- to 18-gauge, and the
number of cores ranged from 4 to 5. The two
MRI-guided biopsies were both 9-gauge, and 12
cores were obtained in each procedure.
Of a total of 31 cases of SA, 12 showed DCIS
and 19 LN. Of the 12 patients with DCIS
involving SA diagnosed on core needle biopsy,
four underwent total mastectomy, six had seg-
mental mastectomy, and two patients were lost
to follow-up. Ten of the 12 cases with known
follow-up reported that four had DCIS involv-
ing either SA or a complex sclerosing lesion (4/
10, 40%), four had only DCIS (4/10, 40%), one
had DCIS with a small 1.8-mm focus of pre-
dominantly tubular carcinoma (1/10, 10%), and
one showed invasive ductal carcinoma on
excision (1/10, 10%), which occurred in a
patient who had a delay of 3 years from diag-
nosis to surgical resection (Table 1).
Patients with high-risk lesions, including
lobular neoplasia involving SA, were presented
at our multi-team clinical management confer-
ence that includes surgery, cancer prevention,
pathology, and radiology. Patients with DCIS
involving SA were assigned to surgical excision
without discussion in the high-risk conference.
For each patient, either chemoprevention,
excision, or radiologic follow-up at regular
intervals was recommended, based on clinical
factors such as whether persistent calcification
remained or whether a radiologic/pathologic
discordance was observed. Patients with a posi-
tive family history for breast cancer (5) were also
counseled to consider excision. Following the
clinical management conference, four patients
underwent total mastectomy (4/19, 21.1%),
four patients had excisional/segmental biopsies
(4/19, 21.1%), nine had radiologic follow-up
only (9/19, 52.6%), and one has not had final
disposition (1/19, 5.3%) (recent case). Of the
patients with surgical follow-up (8 patients),
seven had LCIS (7/8, 87.5%) and one showed
only fibroadenoma and SA with no lobular
neoplasia in the specimen (1/8, 12.5%). No
invasive carcinoma was identified in these latter
patients undergoing surgical excision.
PATHOLOGY
Histomorphologic features commonly seen
with DCIS/LN involving SA included lobulo-
centric architecture as a pattern of growth (31/
31, 100%), thin, attenuated myoepithelial cells
visible by hematoxylin and eosin (H&E) stain at
least focally when focusing up and down on the
lesion (31/31, 100%), and adjacent areas of SA
not involved by neoplasia (29/31, 93.5%)
(Figs. 1, 2). Features that were sometimes seen
included hyaline basement membranes sur-
rounding the lesion (14/31, 45.2%), ductal or
lobular neoplasia apart from the area of
involvement by SA (16/31, 51.6%), and calcifi-
cations associated with DCIS/LN/SA (12/31,
38.7%). Features that were observed but not
commonly seen included desmoplasia (6/31,
19.4%), dense inflammation (4/31, 12.9%), and
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Presentation Treatment Findings Follow-up
1 61 L C SM SA/LCIS A&W 9 years
2 61 L C SM SA/LCIS A&W 9 years
3 56 L C NS N/A A&W 5 years
4 54 L M SM FA, SA only A&W 6 years
5 53 L C TM SA/LCIS, ADH No F/U
6 36 L C, A NS, T N/A A&W 6 years
7 57 L C NS N/A No F/U
8 55 L C NS, T N/A A&W 5 years
9 55 L C NS N/A NSCLC, no breast F/U
10 54 L C NS, T N/A A&W 6 years
11 60 L C NS N/A A&W 2 years
12 43 L C NS N/A A&W 1 year
13 47 L E TM SA/LCIS A&W 2 years
14 48 L C TM LCIS A&W 1 year
15 57 L D SM SA/LCIS A&W 1 year
16 21 L M NS N/A US F/U
17 45 L C TM LCIS A&W\ 1 year
18 51 L C Pending N/A N/A
19 65 L C NS N/A A&W 6 mo.
20 49 D D TM DCIS, LCIS, 1.8-mm focus of inv. Ca
(pred. tubular type)
A&W 11 years
21 66 D C, Di SM DCIS/CSL A&W 4 years
22 49 D C TM IDC, 3 cm with SA/DCIS No F/U
23 34 D C TM DCIS No F/U
24 72 D C TM DCIS Deceased, small cell ca
25 55 D M SM SA/DCIS A&W 4 years
26 52 D A SM SA/DCIS A&W 2 years
27 46 D C UNK UNK UNK
28 64 D C/D SM DCIS A&W 1 year
29 58 D M UNK UNK UNK
30 47 D M SM DCIS Also IDC another site,
same breast






Presentation Treatment Findings Follow-up
31 55 D M SM DCIS/CSL A&W 2 years
A asymmetry, D ductal, L lobular, Di distortion, SM segmental mastectomy, TM total mastectomy, NS no surgery,
T tamoxifen, IDC invasive ductal carcinoma, UNK unknown, A&W alive and well, CSL complex sclerosing lesion, NSCLC
non-small cell lung carcinoma
Fig. 2 Ductal carcinoma in situ (DCIS) involving
sclerosing adenosis, H&E 9200. Note inconspicuous
flattened myoepithelial encasing the high grade carcinoma
in situ cell layer and peri-lobular inflammation
Fig. 1 Ductal carcinoma in situ (DCIS) involving
sclerosing adenosis, H&E 9100. Note pink hyalinized
stroma and flattened myoepithelial cell layer along the
periphery of the in situ carcinoma
Fig. 3 High-power magnification of DCIS involving
sclerosing adenosis with myoepithelial cells enveloping
single neoplastic cells and cell clusters. H&E 9400
Table 2 Histologic characteristics of carcinoma in situ
involving sclerosing adenosis
Feature % of cases
Lobulocentric pattern 100
ME cells visible 100
Separate areas of SA 93.5
Separate areas of DCIS/LN 51.6
Hyaline basement membranes 45.2
Calcifications 38.7
Desmoplasia 19.4
Single cells enveloped by ME cells 19.4
Inflammation 12.9
ME myoepithelial, SA sclerosing adenosis, DCIS ductal
carcinoma in situ, LN lobular neoplasia
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single cells enveloped by myoepithelial cells (6/
31, 19.4%) (Fig. 3) (Table 2).
Immunohistochemistry was used in occa-
sional cases to exclude invasive carcinoma (9/
31, 29.0%), and included a combination of
smooth muscle actin (Sigma, 1:80,000 dilution),
smooth muscle myosin heavy chain (Invitro-
gen, 1:200 dilution) and/or P63 (Biocare, dilu-
tion 1:1000) (Figs. 4, 5). Appropriate quality
checks and controls were utilized according to
manufacturer standards. E-cadherin (Life Tech-
nologies, 1:1000 dilution) was employed in
6/31 cases (19.4%) to differentiate between
ductal and lobular neoplasia (Fig. 6) involving
sclerosing adenosis. Cases of DCIS exhibited
strong membranous E-cadherin staining of the
cells comprising the intraductal carcinoma,
while E-cadherin staining was absent in the
neoplastic cells of LCIS.
DISCUSSION
Core needle biopsy interpretation is a reliable
method for triage of mammographic abnor-
malities. However, the diagnosis of DCIS or
lobular neoplasia involving a sclerosing lesion
on core biopsy may present difficult diagnostic
challenges and frequently can be confused with
invasive carcinoma, leading to over-manage-
ment including inappropriate administration of
chemotherapy or more extensive surgery.
However, when one is familiar with this diag-
nostic pitfall, the diagnosis becomes much
more straightforward, and immunohistochem-
ical stains are not necessary for confirmation of
the diagnosis in most cases.
A review of the English literature revealed
four single case reports and four case series
reports, overall describing 39 total cases of DCIS
and/or LN involving SA. Our case series adds 31
Fig. 5 Smooth muscle actin immunohistochemistry stain
highlights myoepithelial cells enveloping the DCIS involv-
ing adenosis. Inset: p63 immunohistochemical stain shows
nuclear immunoreactivity of myoepithelial cells surround-
ing DCIS
Fig. 6 Lobular neoplasia involving sclerosing adenosis.
Notice nesting pattern of non-cohesive bland uniform cells
distending the sclerosing adenosis and minimizing the
hyalinized pink stroma. Coarse magenta microcalcifica-
tions are easily identified and were likely the impetus for
biopsy
Fig. 4 Smooth muscle actin immunohistochemistry stain
highlights myoepithelial cells enveloping the DCIS
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additional cases to the literature. In the first
described series of six cases of LCIS involving SA
[1], Fechner et al. found that the architecture of
the lesion by low-power assessment was the key
to the correct diagnosis, noting that an invasive
carcinoma should have no overall organiza-
tional pattern. We also found low-power
assessment to be the most useful clue that one is
dealing with an SA. Sclerosing lesions maintain
an organized, lobular architectural pattern. If
one is concerned about invasive carcinoma but
the lesion maintains a lobular architecture at
low power, the possibility of DCIS/LN involving
an SA should be strongly considered.
In a later case series which included both
ductal and lobular cases [2], Rasbridge et al.
commented that the lobular architecture was
sometimes difficult to fully assess due to dis-
tortion by both SA and ductal or lobular neo-
plasia, and that both immunohistochemical
stains and comparison with adjacent adenosis
not involved by ductal or lobular neoplasia were
helpful. We also found that the lobular archi-
tecture is sometimes difficult to assess on core
biopsy, particularly if the lesion of concern is at
the edges of the core biopsy. One extremely
helpful clue in the diagnosis of these cases is the
presence of SA not involved by neoplasia in
other portions of the biopsy. This feature was
found in almost all cases, and provided a reas-
suring ‘‘internal control’’ of the process for
comparison. This finding also provides proof
that a sclerosing process is occurring within the
breast. Another helpful clue occurs when the
neoplastic process does not entirely fill the
sclerosing lesion. When this occurs the periph-
ery of the lobule commonly shows the recog-
nizable histology of a usual sclerosing lesion. In
our experience, if this finding is seen, invasion
is very unlikely.
In difficult cases, immunohistochemical
staining for myoepithelial markers may be
employed. For instance, some of our cases dis-
played occasional neoplastic single cells envel-
oped by myoepithelial cells (identified within
the center of the lobule). Confirmatory
myoepithelial markers should be ordered in
these cases to exclude invasive carcinoma.
Another instance in which immunohisto-
chemical stains should be considered is when
the sclerosing lesion is associated with a dense
inflammatory background. In these cases, both
myoepithelial markers and a pan-cytokeratin
stain may be helpful to confirm the diagnosis of
in situ carcinoma.
In a smaller mixed case series [3], Eusebi et al.
noted that the presence of a PAS-positive basal
lamina and myoepithelial cells were useful
adjuncts to the low-power assessment. We also
noted that the presence of myoepithelial cells in
at least some portions of the lesion was a helpful
feature. Often the myoepithelial cells are thin or
attenuated and are not seen at first glance.
Focusing up and down on the tissue plane (or
immunohistochemical stains) may be
necessary.
Of course, the reason that these lesions are so
important to consider is the real possibility of
confusion with an invasive carcinoma. In the
mixed case series [3] by Eusebi et al., two of the
patients went to mastectomy because they were
originally diagnosed as invasive carcinoma by
frozen section. Other individual case reports
[4–7] were notable for a case of LCIS/SA that was
originally called invasive carcinoma on biopsy.
Some of our cases demonstrated characteristics
which might normally be considered to be
associated with an invasive process, if the
overall architectural clues are not recognized.
Desmoplasia was seen in 19.4% of cases, which
to our knowledge has never been described in
association with these lesions. In addition, sin-
gle cells enveloped by thin, attenuated myoep-
ithelial cells also were present within the center
of the sclerosing lesion in 19.4% of cases. In all
cases, attention to the other criteria helped to
prevent misdiagnosis based on a single
characteristic.
Follow-up data were given for some of the
previous case studies. In the six cases of LCIS
involving SA [1], Fechner et al. found that the
only invasive carcinoma was an incidental
tubular carcinoma, which was located away
from areas of SA. In a later case series which
included both ductal and lobular cases [2],
Rasbridge et al. did not provide patient follow-
up, but noted that three cases had small foci of
invasive carcinoma in addition to ductal or
lobular neoplasia involving SA. In the mixed
case series [3] by Eusebi et al., the patients were
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all alive and well after quadrantectomy or
mastectomy, for a follow-up time ranging from
23 months to 10 years. In a small mixed case
series [8], Oberman et al. selected cases of DCIS/
LCIS which appeared solely in sclerosing
adenosis, with no carcinoma in situ present
outside the sclerosing lesion. Eight of the
patients were followed for an average of 3 years,
and were alive and well. As expected, our fol-
low-up data also indicate that these patients do
extremely well. Of the patients with invasive
ductal carcinoma on excision, one patient
waited 3 years between diagnosis and excision,
with only alternative therapies in the interim.
The only unexpected case of invasive carcinoma
on surgical follow-up was a 1.8-mm focus of
carcinoma which was predominantly of tubular
type, and the patient has been alive and well for
11 years since the diagnosis. Of the patients
with LCIS, all are alive and well (with the
exception of two patients who had a history of
primary lung carcinoma). Despite the known
increased incidence of invasive carcinoma in
these patients, none of the patients with LCIS
involving SA who underwent surgery had
invasive carcinoma in their excisions.
The previously reported cases included 21
lobular, 15 ductal, and 3 combined ductal/lob-
ular neoplasia cases. Our cases showed a very
slight lobular predominance (19 lobular, 12
ductal), a relationship also described by Koerner
[9]. One might expect that because sclerosing
adenosis is an estrogen-dependent lobulocen-
tric process, the incidence of associated lobular
neoplasia would be much higher, but this has
not been demonstrated. One must be careful
not to assume that a low-grade carcinoma
in situ involving sclerosing adenosis is lobular
carcinoma, because ductal cancerization is
almost as frequent. Evaluating for secondary
lumen formation (even in adenosis) and cell
polarization is helpful. An E-cadherin stain can
be employed to help discriminate between the
two entities.
The limitations of this study include the small
sample size of patients who have this uncommon
but clinically relevant diagnosis. Another limita-
tionof the study is the lackof extensive follow-up,
although among patients with DCIS who under-
went excision, 90%had eitherDCIS, or DCISwith
microinvasion. The limited number of cases only
allow for descriptive comparisons of the histol-
ogy. Using descriptive statistics, the top three
features (lobulocentric pattern, visibility of
myoepithelial cells, and separate areas of scleros-
ing adenosis) are statistically more frequently
occurring than what is randomly expected. Core
needle biopsy interpretation of mammographic
abnormalities is a reliable method of assessment,
and diagnosticians must maintain a broad differ-
ential diagnosis that includes mimickers of inva-
sive carcinoma to prevent over-diagnosis and
overtreatment.
CONCLUSION
In summary, we present the largest series of 31
cases of SA involved by DCIS or lobular neoplasia
initially diagnosed on core biopsy. In addition to
the low-power architectural pattern that may be
useful in making the diagnosis, the pathologist
should focus on the attenuated peripherally
located myoepithelial cells and search for carci-
noma in situ in other areas of the biopsymaterial.
Importantly, desmoplasia may be identified in
cases of sclerosing adenosis, and its presence does
not indicate invasive carcinoma, as in our series
only 19.4% of cases demonstrated this finding.
Knowledge of these diagnostic pearls will hope-
fully prevent erroneous diagnosis and over-
management of patients with in situ disease.
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